Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections

Kwamena William Coleman Sagoe*, Kwabena Obeng Duedu, Francesca Ziga, Afrakoma Adjoa Agyei, Theophilus Korku Adiku, Margaret Lartey, Julius Abraham Addo Mingle, Max Arens

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    1 Citation (SciVal)


    BACKGROUND: Co-infection of HIV with HBV is common in West Africa but little information is available on the effects of HBV on short-term therapy for HIV patients. A 28 day longitudinal study was conducted to examine short-term antiretroviral therapy (ART) outcomes in HIV infected individuals with HBV co-infection. METHODS: Plasma from 18 HIV infected individuals co-infected with HBV and matched controls with only HIV infection were obtained at initiation, and 7 and 28 days after ART. HIV-1 viral load changes were monitored. Clinical and demographic data were also obtained from patient folders, and HIV-1 drug resistance mutation and subtype analysis performed. RESULTS: The presence of HBV co-infection did not significantly affect HIV-1 viral load changes within 7 or 28 days. The CD4(+) counts on the other hand of patients significantly affected the magnitude of HIV-1 viral load decline after 7 days (rho = -0.441, p = 0.040), while the pre-ART HIV-1 VL (rho = 0.844, p =
    Original languageEnglish
    Article number38
    JournalAnnals of Clinical Microbiology and Antimicrobials
    Issue number1
    Publication statusPublished (VoR) - 2 Jun 2016


    • Antiretroviral therapy
    • Co-infection
    • Drug resistance
    • Hepatitis B virus
    • Human immunodeficiency virus
    • Short-term therapy


    Dive into the research topics of 'Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections'. Together they form a unique fingerprint.

    Cite this